Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiomyopathy IV: Restrictive Cardiomyopathy

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Septal thickness to QRS voltage ratio in Lead I/aVR: A simple tool for estimating cardiac amyloid burden.

International journal of cardiology·2026

Same author

Cardiological aspects of Fabry disease: from diagnosis to therapeutic efficacy assessment.

Orphanet journal of rare diseases·2026

Same author

Natural History of Asymptomatic Phenotypically Mild HCM: Insights From the SHaRe Registry.

Journal of the American College of Cardiology·2026

Same author

Disease acceptance and socio-familial support in late adolescents and young adults with cardiomyopathy: a pilot study.

BMC psychology·2026

Same author

Multicenter cohort analysis of cardiac amyloidosis patients treated with heart transplant.

Revista espanola de cardiologia (English ed.)·2026

Same author

Differential Transthyretin Stabilization in Patients With Wild Type and Variant Transthyretin Amyloidosis.

JACC. CardioOncology·2026

Search research articles

Related Experiment Video

Updated: Jul 31, 2025

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

Stage-specific therapy for hypertrophic cardiomyopathy.

Alessia Argirò¹, Mattia Zampieri^1,2, Alberto Marchi^1,2

¹Cardiomyopathy Unit, Cardiothoracovascular Department, Careggi University Hospital, Largo Brambilla, 3 50134 Florence, Italy.

European Heart Journal Supplements : Journal of the European Society of Cardiology

|May 1, 2023

Summary

Hypertrophic cardiomyopathy (HCM) is an inherited heart muscle disease. New targeted therapies show promise for improving symptoms and function across all disease stages.

Keywords:

Heart failure Hypertrophic cardiomyopathy Therapy

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Published on: March 1, 2016

Related Experiment Videos

Last Updated: Jul 31, 2025

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Published on: March 1, 2016

Area of Science:

Cardiology
Genetics
Pharmacology

Background:

Hypertrophic cardiomyopathy (HCM) is the most common inherited myocardial disease.
It is characterized by unexplained left ventricular hypertrophy.
Complications include heart failure and arrhythmias like atrial fibrillation and ventricular arrhythmias.

Purpose of the Study:

To review current and emerging treatment strategies for hypertrophic cardiomyopathy (HCM).
To outline therapeutic approaches tailored to different stages of HCM natural history.
To highlight recent advancements in pharmacological agents targeting HCM pathophysiology.

Main Methods:

Review of current literature on hypertrophic cardiomyopathy (HCM) treatments.
Analysis of clinical trial data for novel pharmacological agents.
Synthesis of treatment options based on disease progression: pre-phenotype, classic phenotype, adverse remodeling, and overt dysfunction.

Main Results:

Established treatments include septal reduction, ICDs, and medications like beta-blockers.
New pharmacological agents targeting HCM pathophysiology demonstrate encouraging results.
Improvements in functional capacity and symptom reduction are observed in clinical trials.

Conclusions:

Treatment for HCM requires a phased approach, adapting to disease progression.
Emerging therapies offer new hope for managing symptoms and improving outcomes in HCM patients.
Personalized treatment strategies are crucial for addressing the diverse clinical manifestations of HCM.